Boosting the Brain Delivery of Atazanavir through Nanostructured Lipid Carrier-Based Approach for Mitigating NeuroAIDS

Atazanavir (ATZ) presents poor brain availability when administered orally, which poses a major hurdle in its use as an effective therapy for the management of NeuroAIDS. The utilization of nanostructured lipid carriers (NLCs) in conjunction with the premeditated use of excipients can be a potential...

Descripción completa

Detalles Bibliográficos
Autores principales: Khan, Saif Ahmad, Rehman, Saleha, Nabi, Bushra, Iqubal, Ashif, Nehal, Nida, Fahmy, Usama A., Kotta, Sabna, Baboota, Sanjula, Md, Shadab, Ali, Javed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7694775/
https://www.ncbi.nlm.nih.gov/pubmed/33172119
http://dx.doi.org/10.3390/pharmaceutics12111059

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7694775/
https://www.ncbi.nlm.nih.gov/pubmed/33172119
http://dx.doi.org/10.3390/pharmaceutics12111059

Ejemplares similares